Article Tools

Search for Related Articles

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

15 February 2008

Volume 46, Number 4
Clinical Infectious Diseases 2008;46:584–593
1058-4838/2008/4604-0018$15.00
DOI: 10.1086/525536
CLINICAL PRACTICE INVITED ARTICLE

Role of Folate Antagonists in the Treatment of Methicillin‐Resistant Staphylococcus aureus Infection

Richard A. Proctor

Department of Medical Microbiology/Immunology and Medicine, University of Wisconsin School of Medicine and Public Health, Madison

Methicillin‐resistant Staphylococcus aureus (MRSA) infection has reached epidemic proportions, and therapeutic options are limited because these strains are often multidrug resistant. However, the new strains of community‐acquired MRSA show decreased resistance to trimethoprim‐sulfamethoxazole. Clinical and experimental reports show a mixture of successes and failures with trimethoprim‐sulfamethoxazole treatment. A reason for failure might be the amount of thymidine released from damaged host tissues and bacteria, a concept strengthened by the fact that S. aureus thermonuclease releases thymidine from DNA. Thus, success or failure with trimethoprim‐sulfamethoxazole may well depend on the amount of tissue damage and organism burden, rather than acquisition of a resistance gene. Clinical trials and experimental animal studies show high failure rates, perhaps because of released thymidine. The use of trimethoprim‐sulfamethoxazole for community‐acquired MRSA infection should not be endorsed without further research.

Received 20 July 2007; accepted 9 October 2007; electronically published 15 January 2008.

Reprints or correspondence: Dr. Richard A. Proctor, 5301 Microbial Sciences, University of Wisconsin, 1550 Linden Dr., Madison, WI 53706‐1521 ().

Ellie J. C. Goldstein, Section Editor

Cited by

David Y. Hyun, Edward O. Mason, Andrea Forbes, Sheldon L. Kaplan. (2009) TRIMETHOPRIM-SULFAMETHOXAZOLE OR CLINDAMYCIN FOR TREATMENT OF COMMUNITY-ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS SKIN AND SOFT TISSUE INFECTIONS. The Pediatric Infectious Disease Journal 28:1, 57-59
Online publication date: 1-Feb-2009.
CrossRef
Pablo Yagupsky. (2008) Trimethoprim-Sulfamethoxazole for Osteoarthritis Caused by Staphylococcus aureus or Kingella kingae. The Pediatric Infectious Disease Journal 27:11, 1042-1043
Online publication date: 1-Dec-2008.
CrossRef
S. N. Leonard, G. W. Kaatz, L. R. Rucker, M. J. Rybak. (2008) Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 62:6, 1305-1310
Online publication date: 10-Oct-2008.
CrossRef
J Patrick Powell, Richard P Wenzel. (2008) Antibiotic options for treating community-acquired MRSA. Expert Review of Anti-infective Therapy 6:3, 299-307
Online publication date: 1-Jul-2008.
CrossRef
Close Popup